Distler, F. A. and Pahernik, S. and Gakis, G. and Hutterer, G. and Lebentrau, S. and Rink, M. and Nuhn, P. and Brookman-May, S. and Burger, M. and Gratzke, C. and Wolff, I. and May, M. (2020) Adherence to the EAU guideline recommendations for systemic chemotherapy in penile cancer: results of the E-PROPS study group survey. WORLD JOURNAL OF UROLOGY, 38 (10). pp. 2523-2530. ISSN 0724-4983, 1433-8726
Full text not available from this repository. (Request a copy)Abstract
Objectives To validate the adherence of urologists to chemotherapy recommendations given in the EAU guidelines on PeCa. The European Association of Urology (EAU) guidelines on penile cancer (PeCa) are predominantly based on retrospective studies with low level of evidence. Materials and methods A 14-item-survey addressing general issues of PeCa treatment was developed and sent to 45 European hospitals. 557 urologists participated in the survey of which 43.5%, 19.3%, and 37.2% were in-training, certified, and in leading positions, respectively. Median response rate among participating departments was 85.7% (IQR 75-94%). Three of 14 questions addressed clinical decisions on neoadjuvant, adjuvant, and palliative chemotherapy. Survey results were analyzed by bootstrap-adjusted multivariate logistic-regression-analysis to identify predictors for chemotherapy recommendations consistent with the guidelines. Results Neoadjuvant, adjuvant, and palliative chemotherapy was recommended according to EAU guidelines in 21%, 26%, and 48%, respectively. For neoadjuvant chemotherapy, urologists holding leading positions or performing chemotherapy were more likely to recommend guideline-consistent treatment (OR 1.85 and 1.92 withp((bootstrap)) = 0.007 and 0.003, respectively). Supporting resources (i.e., guidelines, textbooks) were used by 23% of survey participants and significantly improved consistency between treatment recommendations and Guideline recommendations in all chemotherapy settings (p((bootstrap)) = 0.010-0.001). Department size and university center status were no significant predictors for all three endpoints. Conclusions In this study, we found a very low rate of adherence to the EAU guidelines on systemic treatment for PeCa. Further investigations are needed to clarify whether this missing adherence is a consequence of limited individual knowledge level or of the low grade of guideline recommendations.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SQUAMOUS-CELL CARCINOMA; NEOADJUVANT; CISPLATIN; ADJUVANT; 5-FLUOROURACIL; EPIDEMIOLOGY; COMBINATION; METASTASES; TAXANE; Guideline compliance; Penile squamous cell carcinoma; Neoadjuvant chemotherapy; Adjuvant chemotherapy; Palliative chemotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 10 Mar 2021 09:01 |
| Last Modified: | 10 Mar 2021 09:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43722 |
Actions (login required)
 |
View Item |
